糖尿病血管并发症:旧识与新思
本文综述糖尿病微血管和大血管并发症的负担与防治现状,指出多数患者受累,西方多国并发症发生率因协同加速因素被识别并干预而趋稳,但原发启动因素与预防策略仍不明确;主张重拾自然史研究,并借助组学、高分辨影像、计算建模及表观遗传学、能量代谢、微生物群等新方向寻找生物标志物与治疗靶点。
要点
- 糖尿病大血管和微血管并发症累及多数患者,负担随糖尿病流行持续加重。
- 多种协同加速因素及治疗途径已被识别,使多数西方国家并发症发生率趋于稳定。
- 并发症的原发启动因素与预防策略仍不明确,需重拾自然史研究并拓展多学科研究。
核心结论
- 糖尿病并发症的原发启动因素与预防策略仍不明确,需要协调各方力量支持糖尿病研究的各个层面。
研究设计与样本
- 本文为综述,围绕糖尿病微血管和大血管并发症的自然史研究、近期III期试验及新技术与新研究领域进行论述。
主要发现
- 糖尿病微血管和大血管并发症发生在多数患者中,其负担随糖尿病流行而加重。
- 多种协同加速因素被识别并提供治疗途径,使多数西方国家的并发症发生率趋于稳定。
- 近期III期试验中部分化合物的多效性在延缓并发症进展方面可能与其降糖能力同样有益,同时暴露出知识缺口。
- 线粒体活性氧生成等广泛认可的病理通路近期受到质疑。
- 组学、高分辨影像和计算建模等技术进步为强化和重新评估研究结果提供了机会。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In parallel with the growing diabetes pandemic, there is an increasing burden of micro- and macrovascular complications, occurring in the majority of patients. The identification of a number of synergistic accelerators of disease, providing therapeutic pathways, has stabilised the incidence of complications in most western nations. However, the primary instigators of diabetic complications and, thus, prevention strategies, remain elusive. This has necessitated a refocus on natural history studies, where tissue and plasma samples are sequentially taken to determine when and how disease initiates. In addition, recent Phase III trials, wherein the pleiotropic effects of compounds were arguably as beneficial as their glucose-lowering capacity in slowing the progression of complications, have identified knowledge gaps. Recently the influence of other widely recognised pathological pathways, such as mitochondrial production of reactive oxygen species, has been challenged, highlighting the need for a diverse and robust global research effort to ascertain viable therapeutic targets. Technological advances, such as -omics, high-resolution imaging and computational modelling, are providing opportunities for strengthening and re-evaluating research findings. Newer areas such as epigenetics, energetics and the increasing scrutiny of our synergistic inhabitants, the microbiota, also offer novel targets as biomarkers. Ultimately, however, this field requires concerted lobbying to support all facets of diabetes research.
引用
- Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia. 2017. PMID: 28725914. doi:10.1007/s00125-017-4360-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。